WO2001070801A1 - Nouveau polypeptide, arn helicase humaine 34, et polynucleotide codant pour ce polypeptide - Google Patents
Nouveau polypeptide, arn helicase humaine 34, et polynucleotide codant pour ce polypeptide Download PDFInfo
- Publication number
- WO2001070801A1 WO2001070801A1 PCT/CN2001/000244 CN0100244W WO0170801A1 WO 2001070801 A1 WO2001070801 A1 WO 2001070801A1 CN 0100244 W CN0100244 W CN 0100244W WO 0170801 A1 WO0170801 A1 WO 0170801A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- polynucleotide
- rna helicase
- human rna
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
Definitions
- the present invention belongs to the field of biotechnology. Specifically, the present invention describes a novel polypeptide, human RNA helicase 34, and a polynucleotide sequence encoding the polypeptide. The invention also relates to the preparation method and application of the polynucleotide and the polypeptide.
- RNA structure In many activities of the cell, the regulation of the RNA structure, such as splicing of the precursor RM, assembly of the spliceosome, and protein translation are required. These processes are usually regulated by a variety of different RNA helicases.
- RM helicases from different sources constitute a large family of proteins, which can be detected in many biological systems where RNA plays an important role. They are widely distributed in various tissues and organs from prokaryotes (including viruses) to lower and higher organisms. They are involved in cell and mitochondrial division, RNA editing, rRNA processing, transcription initiation, nuclear niRNA transport, and mRNA. Degradation and other processes.
- RNA helicases are considered to be important factors in cell development and differentiation, and some of them also play a role in the transcription and replication of viral single-stranded RNA [Arri Eisen, John C. Lucchesi, Bioessays, 1998, 20: 634 -641]. It provides effective means for the diagnosis, prevention and treatment of cancer, nervous system diseases and immune system diseases in vivo.
- RNA helicases are divided into different subfamilies, subfamily I and subfamily ⁇ according to their structural characteristics. All helicases contain two Walker-type NTP binding domains-an A domain (or ATPase A domain) and a B domain (or ATPase B domain). Members of subfamily I contain a conserved ATPase A domain: GXXXXGKT. Later, it was found that some ATPase domain A of some RNA helicases have mutations in some amino acid sites. The conserved sequence of the ATPase A domain is: AXXGXGKT, so these proteins are divided into one class, namely subfamily II .
- DEAD box protein In subfamily II, some proteins contain a conserved DEAD box in the ATPase domain B. It was discovered that members of this subfamily can be divided into three different subclasses according to their DEAD boxes, namely DEAD boxes. Protein, DEAH box protein and DEXH box protein [Angelika Luking, Ulf Stahl et al., 1998, Crit. Rev. Biochem. Mol. Biol., 33: 259-296].
- Zhang S. et al. Cloned NDHII protein from bovine, which is a member of the RNA helicase family containing DEAD box. It contains the DEIH motif in its domain II. This protein also has high homology with human helicase A and Drosophila Mle protein. All three are thought to play important roles in the metabolism of nuclear DNA and RNA [Zhang S., Maacke H. et al., 1995, J. Biol.
- RNA helicase A has both RNA helicase activity and DNA helicase activity in vivo. Therefore, the enzyme plays an important biological function in the process of RNA transcription regulation [Lee CG, Ek i T et al., 1998, Genomi cs, 47: 365-371]. It can be known from the above that members of the RNA helicase protein family containing the DEAD box play an important biological function in the transcriptional regulation of RNA. The abnormal expression of such proteins will cause some metabolic disorders caused by abnormal transcriptional regulation. A variety of immune system diseases and malignant diseases of some related tissues.
- the human RM helicase 34 protein plays an important role in regulating important functions of the body such as cell division and embryonic development, and it is believed that a large number of proteins are involved in these regulatory processes, so there has been a need to identify more involved in these processes.
- the human RNA helicase 34 protein in particular, identifies the amino acid sequence of this protein.
- the isolation of the new human RNA helicase 34 protein encoding gene also provides a basis for research to determine the role of this protein in health and disease states. This protein may form the basis for the development of diagnostic and / or therapeutic drugs for the disease, so it is important to isolate its coding DNA.
- Another object of the invention is to provide a polynucleotide encoding the polypeptide.
- Another object of the present invention is to provide a recombinant vector containing a polynucleotide encoding human RNA helicase 34.
- Another object of the invention is to provide a genetically engineered host cell containing a polynucleotide encoding human RNA helicase 34.
- Another object of the present invention is to provide a method for producing human RNA helicase 34.
- Another object of the present invention is to provide an antibody against the polypeptide of the present invention, human NA helicase 34.
- Another object of the present invention is to provide analog compounds, antagonists, agonists, and inhibitors against the polypeptide-human RNA helicase 34 of the present invention.
- Another object of the present invention is to provide diagnosis and treatment of diseases related to abnormalities of human RNA helicase 34 Methods. Summary of invention
- the present invention relates to an isolated polypeptide, which is of human origin and comprises: a polypeptide having the amino acid sequence of SEQ ID No. 2, or a conservative variant, biologically active fragment or derivative thereof.
- the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: 2.
- the invention also relates to an isolated polynucleotide comprising a nucleotide sequence or a variant thereof selected from the group consisting of:
- sequence of the polynucleotide is one selected from the group consisting of: (a) a sequence having positions 260-1 to 177 in SEQ ID NO: 1; and (b) a sequence having 1- in SEQ ID NO: 1 2709-bit sequence.
- the present invention further relates to a vector, particularly an expression vector, containing the polynucleotide of the present invention; a host cell genetically engineered with the vector, including a transformed, transduced or transfected host cell; Host cell and method of preparing the polypeptide of the present invention by recovering the expression product.
- the invention also relates to an antibody capable of specifically binding to a polypeptide of the invention.
- the invention also relates to a method for screening compounds that mimic, activate, antagonize or inhibit the activity of human RNA helicase 34 protein, which comprises utilizing the polypeptide of the invention.
- the invention also relates to compounds obtained by this method.
- the invention also relates to a method for detecting a disease or disease susceptibility related to abnormal expression of human RNA helicase 34 protein in vitro, comprising detecting a mutation in the polypeptide or a polynucleotide sequence encoding the same in a biological sample, or detecting a biological The amount or biological activity of a polypeptide of the invention in a sample.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a polypeptide of the invention or a mimetic thereof, an activator, an antagonist or an inhibitor, and a pharmaceutically acceptable carrier.
- the present invention also relates to the use of the polypeptide and / or polynucleotide of the present invention in the preparation of a medicament for treating cancer, developmental disease or immune disease or other diseases caused by abnormal expression of human RNA helicase 34.
- Fig. 1 is a comparison diagram of gene chip expression profiles of human RNA helicase 34 and human RNA helicase 95 of the present invention.
- the upper graph is a graph of the expression profile of human RNA helicase 34
- the lower graph is the graph of the expression profile of human RNA helicase 95.
- Figure 2 shows the polyacrylamide gel electrophoresis (SDS-PAGE) of the isolated human RNA helicase 34.
- 34kDa is the molecular weight of the protein.
- the arrow indicates the isolated protein band.
- Nucleic acid sequence refers to an oligonucleotide, a nucleotide or a polynucleotide and a fragment or part thereof, and may also refer to a genomic or synthetic DNA or RNA, they can be single-stranded or double-stranded, representing the sense or antisense strand.
- amino acid sequence refers to an oligopeptide, peptide, polypeptide or protein sequence and fragments or portions thereof.
- amino acid sequence in the present invention relates to the amino acid sequence of a naturally occurring protein molecule, such "polypeptide” or “protein” does not mean to limit the amino acid sequence to a complete natural amino acid related to the protein molecule .
- a “variant" of a protein or polynucleotide refers to an amino acid sequence having one or more amino acids or nucleotide changes or a polynucleotide sequence encoding it.
- the changes may include deletions, insertions or substitutions of amino acids or nucleotides in the amino acid sequence or nucleotide sequence.
- Variants can have "conservative" changes, in which the amino acid substituted has a structural or chemical property similar to the original amino acid, such as replacing isoleucine with leucine.
- Variants can also have non-conservative changes, such as replacing glycine with tryptophan.
- “Deletion” refers to the deletion of one or more amino acids or nucleotides in an amino acid sequence or nucleotide sequence.
- Insertion means that a change in the amino acid sequence or nucleotide sequence results in an increase in one or more amino acids or nucleotides compared to a molecule that exists in nature.
- Replacement refers to the replacement of one or more amino acids or nucleotides with different amino acids or nucleotides.
- Bioactivity refers to a protein that has the structure, regulation, or biochemical function of a natural molecule.
- immunologically active refers to the ability of natural, recombinant or synthetic proteins and fragments thereof to induce a specific immune response and to bind specific antibodies in a suitable animal or cell.
- An "agonist” refers to a molecule that, when combined with human RNA helicase 34, causes a change in the protein to regulate the activity of the protein.
- Agonists can include proteins, nucleic acids, carbohydrates or any Any other molecule that can bind human RNA helicase 34.
- Antagonist refers to a molecule that, when combined with human RNA helicase 34, can block or regulate the biological or immunological activity of human RNA helicase 34.
- Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates or any other molecule that can bind human RNA helicase 34.
- RNA helicase 34 refers to a change in the function of human RNA helicase 34, including an increase or decrease in protein activity, a change in binding characteristics, and any other biological, functional, or immune properties of human RNA helicase 34.
- substantially pure ' means substantially free of other proteins, lipids, sugars or other substances with which it is naturally associated.
- Those skilled in the art can purify human RNA helicase 34 using standard protein purification techniques. Basically Pure human RNA helicase 34 can generate a single main band on a non-reducing polyacrylamide gel. The purity of human RNA helicase 34 polypeptide can be analyzed by amino acid sequence.
- Complementary refers to the natural binding of polynucleotides by base-pairing under conditions of acceptable salt concentration and temperature.
- sequence C-T-G-A
- complementary sequence G-A-C-T.
- the complementarity between two single-stranded molecules may be partial or complete.
- the degree of complementarity between nucleic acid strands has a significant effect on the efficiency and strength of hybridization between nucleic acid strands.
- “Homology” refers to the degree of complementarity and can be partially homologous or completely homologous.
- Partial homology refers to a partially complementary sequence that at least partially inhibits hybridization of a fully complementary sequence to a target nucleic acid. The inhibition of such hybridization can be detected by performing hybridization (Southern imprinting or Northern blotting, etc.) under conditions of reduced stringency. Substantially homologous sequences or hybridization probes can compete and inhibit the binding of fully homologous sequences to the target sequence under conditions of reduced stringency. This does not mean that the conditions of reduced stringency allow non-specific binding, because the conditions of reduced stringency require that the two sequences bind to each other as a specific or selective interaction.
- Percent identity refers to the percentage of sequences that are the same or similar in a comparison of two or more amino acid or nucleic acid sequences.
- the percent identity can be determined electronically, such as by the MEGALIGN program (Lasergene sof tware package, DNASTAR, Inc., Mad Son Wis.).
- the MEGALIGN program can compare two or more sequences (Higgins, DG and PM Sharp (1988) Gene 73: 237-244) according to different methods such as the Cluster method. The distance between the pairs arranges each group of sequences into clusters. The clusters are then allocated in pairs or groups.
- the percent identity between two amino acid sequences such as sequence A and sequence B is calculated by the following formula:
- Nucleic acid sequences can also be determined by the Cluster method or by methods known in the art such as Jo tun He in. Percent identity (He in L, (1 990) Me t hods in enzymo l ogy 1 83: 625-645) 0 "Similarity” refers to the identity of the amino acid residues in the corresponding positions when the amino acid sequences are aligned. Or the extent of conservative substitution.
- Amino acids used for conservative substitution may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; having an uncharged head group is Similar hydrophilic amino acids may include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.
- Antisense refers to a nucleotide sequence that is complementary to a particular DNA or RNA sequence.
- Antisense strand refers to a nucleic acid strand that is complementary to a “sense strand.”
- Derivative refers to HFP or a chemical modification of its nucleic acid. This chemical modification may be a substitution of a hydrogen atom with a fluorenyl, acyl or amino group. Nucleic acid derivatives can encode polypeptides that retain the main biological properties of natural molecules.
- Antibody refers to an intact antibody molecules and fragments thereof, such as Fa, F (a b ') 2 and F V, which specifically binds to human RNA helicase 34 antigenic determinants.
- a “humanized antibody” refers to an antibody in which the amino acid sequence of a non-antigen binding region is replaced to become more similar to a human antibody, but still retains the original binding activity.
- isolated refers to the removal of matter from its original environment (for example, its natural environment if it is naturally occurring).
- a naturally occurring polynucleotide or polypeptide is not isolated when it is present in a living thing, but the same polynucleotide or polypeptide is separated from some or all of the substances that coexist with it in the natural system.
- Such a polynucleotide may be part of a vector, or such a polynucleotide or polypeptide may be part of a composition. Since the carrier or composition is not a component of its natural environment, they are still isolated.
- isolated refers to the separation of a substance from its original environment (if it is a natural substance, the original environment is the natural environment).
- polynucleotides and polypeptides in a natural state in a living cell are not isolated and purified, but the same polynucleotides or polypeptides are separated and purified if they are separated from other substances in the natural state .
- isolated human RNA helicase 34 means that human RNA helicase 34 is substantially free of other proteins, lipids, sugars, or other substances with which it is naturally associated. Those skilled in the art can purify human RNA helicase 34 using standard protein purification techniques. Substantially pure polypeptides produce a single main band on a non-reducing 'polyacrylamide gel. The purity of the human RNA helicase 34 peptide can be analyzed by amino acid sequence.
- the present invention provides a new polypeptide, human RM helicase 34, which is basically composed of the amino acid sequence shown in SEQ ID NO: 2.
- the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, a synthetic polypeptide, A recombinant polypeptide is preferred.
- the polypeptides of the present invention can be naturally purified products or chemically synthesized products, or can be produced from prokaryotic or eukaryotic hosts (such as bacteria, yeast, higher plants, insects, and mammalian cells) using recombinant techniques. Depending on the host used in the recombinant production protocol, the polypeptide of the invention may be glycosylated, or it may be non-glycosylated. Polypeptides of the invention may also include or exclude starting methionine residues.
- the invention also includes fragments, derivatives and analogs of human RNA helicase 34.
- fragment refers to a polypeptide that substantially retains the same biological function or activity of the human RNA helicase 34 of the present invention.
- a fragment, derivative or analog of the polypeptide of the present invention may be: (I) a kind in which one or more amino acid residues are substituted with conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the substitution
- the amino acid may or may not be encoded by a genetic codon; or ( ⁇ ) a type in which a group on one or more amino acid residues is replaced by another group to include a substituent; or ( ⁇ ⁇ )
- Such a polypeptide sequence in which the mature polypeptide is fused with another compound such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol
- a polypeptide sequence in which an additional amino acid sequence is fused into the mature polypeptide (Such as the leader or secretory sequence or the sequence used to purify the polypeptide or protease sequence).
- such fragments, and their derivatives and analogs are considered to be within the knowledge of those skilled in the art.
- the present invention provides an isolated nucleic acid (polynucleotide), which basically consists of a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2.
- the polynucleotide sequence of the present invention includes the nucleotide sequence of SEQ ID NO: 1.
- the polynucleotide of the present invention is found from a cDNA library of human fetal brain tissue. It contains a full-length polynucleotide sequence of 2709 bases, and its open reading frame of 260-1 177 encodes 305 amino acids. According to the comparison of gene chip expression profiles, it was found that this peptide has a similar expression profile to human R helicase 95, and it can be deduced that the human RNA helicase 34 has similar functions to human RNA helicase 95.
- the polynucleotide of the present invention may be in the form of DNA or RNA.
- DNA forms include cDNA, genomic DNA, or synthetic DNA.
- DNA can be single-stranded or double-stranded.
- DNA can be coding or non-coding.
- the coding region sequence encoding a mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant.
- a "degenerate variant" refers to a nucleic acid sequence encoding a protein or polypeptide having SEQ ID NO: 2 but different from the coding region sequence shown in SEQ ID NO: 1 in the present invention.
- the polynucleotide encoding the mature polypeptide of SEQ ID NO: 2 includes: only the coding sequence of the mature polypeptide; the coding sequence of the mature polypeptide and various additional coding sequences; the coding sequence of the mature polypeptide (and optional additional coding sequences); Coding sequence.
- polynucleotide encoding a polypeptide means including a polynucleotide encoding the polypeptide and including additional Coding and / or non-coding polynucleotides.
- the invention also relates to variants of the polynucleotides described above, which encode polypeptides or fragments, analogs and derivatives of polypeptides having the same amino acid sequence as the invention.
- Variants of this polynucleotide can be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
- an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .
- the invention also relates to a polynucleotide that hybridizes to the sequence described above (having at least 50%, preferably 70% identity, between the two sequences).
- the present invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the present invention under stringent conditions.
- “strict conditions” means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1% SDS, 60 ° C; or (2) added during hybridization Use a denaturant, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42'C, etc .; or (3) the identity between the two sequences is at least 95% Above, more preferably 97% or more hybridization occurs.
- the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO: 2.
- nucleic acid fragments that hybridize to the sequences described above.
- a "nucleic acid fragment” contains at least 10 nucleotides in length, preferably at least 20-30 nucleotides, more preferably at least 50-60 nucleotides, and most preferably at least 100 nuclei. Glycylic acid or more. Nucleic acid fragments can also be used in nucleic acid amplification techniques, such as PCR, to identify and / or isolate polynucleotides encoding human RNA helicase 34.
- polypeptides and polynucleotides in the present invention are preferably provided in an isolated form and are more preferably purified to homogeneity.
- the specific polynucleotide sequence encoding the human RNA helicase 34 of the present invention can be obtained by various methods.
- polynucleotides are isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect homologous polynucleotide sequences, and 2) antibody screening of expression libraries to detect cloned polynucleosides with common structural characteristics Acid fragments.
- the DNA fragment sequence of the present invention can also be obtained by the following methods: 1) separating the double-stranded DM sequence from the genomic DNA; 2) chemically synthesizing the DNA sequence to obtain the double-stranded DNA of the polypeptide.
- genomic DNA isolation is the least commonly used. Direct chemical synthesis of the D sequence is often the method of choice.
- the more commonly used method is the isolation of cDNA sequences.
- the standard method for isolating the cDNA of interest is to isolate mRNA from donor cells that overexpress the gene and perform reverse transcription to form a plasmid or phage cDNA library.
- the construction of cDNA libraries is also a common method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989).
- Commercially available cDNA libraries are also available, such as different cDNA libraries from Clontech. When polymerase reaction technology is used in combination, even very small expression products can be cloned.
- the genes of the present invention can be selected from these cDNA libraries by conventional methods. These methods include (but are not limited to): (l) DNA-DNA or DNA-RNA hybrids; (2) the presence or absence of marker gene functions; (3) measuring the level of human RNA helicase 34 transcripts; (4) ) Detection of protein products expressed by genes through immunological techniques or determination of biological activity. The above methods can be used singly or in combination.
- the probe used for hybridization is homologous to any part of the polynucleotide of the present invention, and its length is at least 10 nucleotides, preferably at least 30 nucleotides, more preferably At least 50 nucleotides, preferably at least 100 nucleotides.
- the length of the probe is usually within 2000 nucleotides, preferably within 1000 nucleotides.
- the probe used here is generally a DNA sequence chemically synthesized based on the gene sequence information of the present invention.
- the genes or fragments of the present invention can of course be used as probes.
- DNA probes can be labeled with radioisotopes, luciferin, or enzymes (such as alkaline phosphatase).
- immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA) can be used to detect protein products expressed by the human RNA helicase 34 gene.
- ELISA enzyme-linked immunosorbent assay
- a method using PCR technology to amplify DNA / RNA is preferably used to obtain the gene of the present invention.
- the RACE method RACE-rapid cDNA end rapid amplification method
- the primers used for PCR can be appropriately based on the polynucleotide sequence information of the present invention disclosed herein. Select and synthesize using conventional methods.
- the amplified DNA / RNA fragments can be isolated and purified by conventional methods such as by gel electrophoresis.
- polynucleotide sequence of the gene of the present invention or various DNA fragments and the like obtained as described above can be measured by a conventional method such as dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such polynucleotide sequences can also be determined using commercial sequencing kits and the like. In order to obtain the full-length cDNA sequence, sequencing needs to be repeated. Sometimes it is necessary to determine the cDNA sequence of multiple clones in order to splice into a full-length cDNA sequence.
- the present invention also relates to a vector comprising the polynucleotide of the present invention, and a host cell produced by genetic engineering using the vector of the present invention or directly using a human RNA helicase 34 coding sequence, and a method for producing a polypeptide of the present invention by recombinant technology. .
- a polynucleotide sequence encoding human RNA helicase 34 can be inserted into a vector to constitute a recombinant vector containing the polynucleotide of the present invention.
- vector refers to bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors well known in the art.
- Vectors suitable for use in the present invention include, but are not limited to: T7 promoter-based expression vectors for expression in bacteria (Rosenberg, et al.
- any plasmid and vector can be used to construct a recombinant expression vector.
- An important feature of expression vectors is that they usually contain an origin of replication, a promoter, a marker gene, and translational regulatory elements.
- RNA sequence encoding human RNA helicase 34 and appropriate transcription / translation regulatory elements. These methods include in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombination technology (Sambroook, et al. Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989).
- the DNA sequence can be operably linked to an appropriate promoter in an expression vector to guide mRNA synthesis. Representative examples of these promoters are: the lac or trp promoter of E.
- the expression vector also includes a ribosome binding site and a transcription terminator for translation initiation. Insertion of enhancer sequences into the vector will enhance its transcription in higher eukaryotic cells. Enhancers are cis-acting factors for DNA expression, usually about 10 to 300 base pairs, which act on promoters to enhance gene transcription. Illustrative examples include SV40 enhancers of 100 to 270 base pairs on the late side of the origin of replication, polytumor enhancers and adenoviral enhancers on the late stage of the origin of replication.
- the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
- selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
- GFP fluorescent protein
- tetracycline or ampicillin resistance for E. coli.
- a polynucleotide encoding human RNA helicase 34 or a recombinant vector containing the polynucleotide can be transformed or transduced into a host cell to constitute a genetically engineered host cell containing the polynucleotide or the recombinant vector.
- the term "host cell” refers to a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples are: E.
- coli Streptomyces
- bacterial cells such as Salmonella typhimurium
- fungal cells such as yeast
- plant cells such as insect cells such as Fly S2 or Sf9
- animal cells such as CH0, COS or Bowes melanoma cells.
- Transformation of a host cell with a DM sequence according to the present invention or a recombinant vector containing the DNA sequence can be performed by conventional techniques well known to those skilled in the art.
- the host is a prokaryote such as E. coli
- competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated with the CaCl 2 method. It is well known in the art. Alternatively, MgCl 2 is used. If necessary, transformation can also be performed by electroporation.
- the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate co-precipitation method, or conventional mechanical methods such as microinjection, electroporation, and liposome packaging.
- the polynucleotide sequence of the present invention can be used to express or produce recombinant human RNA helicase 34 (Sc ience, 1984; 224: 1431). Generally there are the following steps:
- the medium used in the culture may be selected from various conventional mediums. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
- a suitable method such as temperature conversion or chemical induction
- the recombinant polypeptide may be coated in a cell, expressed on a cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be isolated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. These methods include, but are not limited to: conventional renaturation treatment, protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
- conventional renaturation treatment protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid
- polypeptides of the present invention can be directly used in the treatment of diseases, for example, they can treat malignant tumors, adrenal deficiency, skin diseases, various types of inflammation, HIV infection, and immune diseases.
- RNA and DNA helicases are expressed in cancer tissues, brain and nervous tissues, and tissues associated with inflammation and immune responses. Therefore, RNA helicases play an important role in cancer, nervous system diseases, and immune system diseases. In particular, the expression of RNA helicase is significantly increased in cancer and immune system diseases; in nervous system-related diseases, its expression level or activity is reduced.
- the novel human RNA helicase of the present invention can be used for the diagnosis and treatment of diseases related to the nervous system, including but not limited to the following, sedation panic disorder, premature senility Dementia, memory anterograde amnesia, amyotrophic lateral sclerosis, bipolar neurocytic disorder, tension, brain tumors, dementia, depression, delayed dyskinesia, dystonia, epilepsy, hereditary chronic chorea, multiple Lateral sclerosis, neurofibromas, Parkinson's disease, paranoid neuropathy, schizophrenia, Tourette's disease, etc.
- diseases related to the nervous system including but not limited to the following, sedation panic disorder, premature senility Dementia, memory anterograde amnesia, amyotrophic lateral sclerosis, bipolar neurocytic disorder, tension, brain tumors, dementia, depression, delayed dyskinesia, dystonia, epilepsy, hereditary chronic chorea, multiple Lateral sclerosis, neurofibromas, Parkinson's disease,
- novel human helicases and fragments or derivatives thereof of the present invention can also be used to diagnose and treat some cancers, including but not limited to the following, adenoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, etc .;
- cancers including these tissues, thyroid, bladder, bone, bone marrow, brain, breast, cervix, tendon sheath cyst, heart, kidney, lung, liver, muscle, ovary, pancreas, parathyroid gland, prostate, uterus, Salivary glands, skin, spleen, testes, penis, thymus, gallbladder, gastrointestinal tract, etc.
- novel human helicases and fragments or derivatives thereof of the present invention can also be used to diagnose and treat diseases related to the immune system, including but not limited to the following, rheumatoid arthritis, chronic active hepatitis, primary Sjogren's syndrome, ankylosing spondylitis, hemochromatosis, immune complex glomerulonephritis, mycocarditis after gonococcal infection, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, polymyositis, mouth Xerophthalmia syndrome, nodular polyarteritis, Wegener's granulomatosis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, immune thrombocytopenic purpura, insulin autoimmune syndrome, autoimmune Immune thyroid disease, autoimmune heart disease, Down syndrome, short limb sclerosis, hereditary transcobalamin II deficiency with hypogammaglob
- novel human helicases and fragments or derivatives thereof of the present invention can also be used to diagnose and treat diseases related to the immune system, including but not limited to the following, pulmonary eosinophilia, sarcoidosis, rheumatism Arthritis, rheumatoid arthritis, osteoarthritis, cholecystitis, glomerulonephritis, immune complex glomerulonephritis, acute anterior uveitis, osteoporosis, dermatomyositis, urticaria, Specific dermatitis, hemochromatosis, polymyositis, Addison's disease, Graves' disease, chronic active hepatitis, emergency bowel syndrome, atrophic gastritis, systemic lupus erythematosus, myasthenia gravis, cerebral spinal cord Multiple sclerosis, Guillain-Barre syndrome, intracranial granuloma, Wegener's granulomatosis,
- the invention also provides methods for screening compounds to identify agents that increase (agonist) or suppress (antagonist) human RNA helicase 34.
- Agonists enhance human RNA helicase 34 to stimulate biological functions such as cell proliferation, while antagonists prevent and treat disorders related to excessive cell proliferation, such as various cancers.
- mammalian cells or membrane preparations expressing human RNA helicase 34 can be cultured together with labeled human RNA helicase 34 in the presence of a drug. The ability of the drug to increase or block this interaction is then determined.
- Antagonists of human RM helicase 34 include screened antibodies, compounds, receptor deletions and classes Like things. Antagonists of human RNA helicase 34 can bind to human RNA helicase 34 and eliminate its function, or inhibit the production of the polypeptide, or bind to the active site of the polypeptide such that the polypeptide cannot perform biological functions.
- human RNA helicase 34 When screening compounds as antagonists, human RNA helicase 34 can be added to bioanalytical assays to determine whether a compound is an antagonist by measuring the effect of the compound on the interaction between human RNA helicase 34 and its receptor. . Receptor deletions and analogs that act as antagonists can be screened in the same manner as described above for screening compounds. Polypeptide molecules capable of binding to human RNA helicase 34 can be obtained by screening a random peptide library composed of various possible combinations of amino acids bound to a solid phase. When screening, the human RNA helicase 34 molecule should generally be labeled.
- the present invention provides a method for producing antibodies using polypeptides, and fragments, derivatives, analogs or cells thereof as antigens. These antibodies can be polyclonal or monoclonal antibodies.
- the invention also provides antibodies against human RNA helicase 34 epitopes. These antibodies include (but are not limited to): Doklon antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments, and fragments produced by Fab expression libraries.
- Polyclonal antibodies can be produced by injecting human RNA helicase 34 directly into immunized animals (such as rabbits, mice, rats, etc.).
- immunized animals such as rabbits, mice, rats, etc.
- a variety of adjuvants can be used to enhance the immune response, including but not limited to Freund's adjuvant. Wait.
- Techniques for preparing monoclonal antibodies to human RNA helicase 34 include, but are not limited to, hybridoma technology (Kohler and Miste in. Nature, 1975, 256: 495-497), triple tumor technology, human beta-cell hybridization Tumor technology, EBV-hybridoma technology, etc.
- a mosaic antibody combining a human constant region and a non-human-derived variable region can be produced using existing technologies (Morrison et al, PNAS, 1985, 81: 6851).
- the existing technology for producing single chain antibodies (U.S. Pat No. 4946778) can also be used to produce single chain antibodies against human RM helicase 34.
- Antibodies to human RNA helicase 34 can be used in immunohistochemistry to detect human RNA helicase 34 in biopsy specimens.
- Monoclonal antibodies that bind to human RNA helicase 34 can also be labeled with radioisotopes and injected into the body to track their location and distribution. This radiolabeled antibody can be used as a non-invasive diagnostic method to locate tumor cells and determine whether there is metastasis.
- Antibodies can also be used to design immunotoxins that target a particular part of the body.
- human RNA helicase 34 high-affinity monoclonal antibodies can covalently bind to bacterial or plant toxins (such as diphtheria toxin, ricin, ormosine, etc.).
- a common method is to attack the amino group of an antibody with a thiol cross-linking agent such as SPDP and bind the toxin to the antibody through the exchange of disulfide bonds.
- This hybrid antibody can be used to kill human RNA helicase 34 positive cells .
- the antibodies of the present invention can be used to treat or prevent diseases related to human RNA helicase 34. Administration of an appropriate dose of the antibody can stimulate or block the production or activity of human RNA helicase 34.
- the invention also relates to a diagnostic test method for quantitative and localized detection of human RNA helicase 34 levels. These tests are well known in the art and include FISH assays and radioimmunoassays. The level of human RNA helicase 34 detected in the test can be used to explain the importance of human RNA helicase 34 in various diseases and to diagnose diseases in which human RNA helicase 34 plays a role.
- polypeptide of the present invention can also be used for peptide mapping analysis.
- the polypeptide can be specifically cleaved by physical, chemical or enzymatic analysis, and subjected to one-dimensional or two-dimensional or three-dimensional gel electrophoresis analysis, more preferably mass spectrometry analysis.
- Polynucleotides encoding human RNA helicase 34 can also be used for a variety of therapeutic purposes. Gene therapy technology can be used to treat abnormal cell proliferation, development or metabolism caused by the non-expression or abnormal / inactive expression of human RNA helicase 34.
- Recombinant gene therapy vectors (such as viral vectors) can be designed to express mutated human RNA helicase 34 to inhibit endogenous human RNA helicase 34 activity.
- a mutated human RNA helicase 34 may be a shortened human RNA helicase 34 lacking a signaling domain, and although it can bind to a downstream substrate, it lacks signaling activity.
- recombinant gene therapy vectors can be used to treat diseases caused by abnormal expression or activity of human helicase 34.
- Virus-derived expression vectors such as retrovirus, adenovirus, adenovirus-associated virus, herpes simplex virus, parvovirus, etc. can be used to transfer a polynucleotide encoding human RNA helicase 34 into a cell.
- Methods for constructing recombinant viral vectors carrying a polynucleotide encoding human RNA helicase 34 can be found in existing literature (Sambrook, et al.).
- recombinant polynucleotide encoding human RNA helicase 34 can be packaged into liposomes and transferred into cells.
- Methods for introducing a polynucleotide into a tissue or cell include: directly injecting the polynucleotide into a tissue in vivo; or introducing the polynucleotide into a cell in vitro through a vector (such as a virus, phage, or plasmid), and then transplanting the cell Into the body and so on.
- a vector such as a virus, phage, or plasmid
- Oligonucleotides including antisense RNA and DNA
- ribozymes that inhibit human RNA helicase 34 mRNA are also within the scope of the present invention.
- a ribozyme is an enzyme-like RNA molecule that specifically decomposes specific RNA. Its mechanism of action is that the ribozyme molecule specifically hybridizes with a complementary target RNA for endonucleation.
- Antisense RNA, DM, and ribozymes can be obtained using any existing RNA or DNA synthesis technology, such as solid-phase phosphate amide chemical synthesis to synthesize oligonucleotides.
- Antisense RNA molecules can be obtained by in vitro or in vivo transcription of a DNA sequence encoding the RNA.
- This DNA sequence has been integrated downstream of the RNA polymerase promoter of the vector.
- it can be modified in a variety of ways, such as increasing the sequence length on both sides, and the linkage between ribonucleosides using phosphorothioate or peptide bonds instead of phosphodiester bonds.
- Polynucleotides encoding human RNA helicase 34 are useful for diseases related to human RNA helicase 34 Diagnosis.
- the polynucleotide encoding human RNA helicase 34 can be used to detect the expression of human RNA helicase 34 or the abnormal expression of human RNA helicase 34 in a disease state.
- the DNA sequence encoding human RNA helicase 34 can be used to hybridize biopsy specimens to determine the expression of human RNA helicase 34.
- Hybridization techniques include Sou thern blotting, Nor thern blotting, and in situ hybridization. These techniques and methods are publicly available and mature, and related kits are commercially available.
- Part or all of the polynucleotides of the present invention can be used as probes to be fixed on a microarray (Microray ray) or a DNA chip (also known as a "gene chip") for analyzing differential expression analysis of genes and genes in tissues diagnosis.
- Human RNA helicase 34 specific primers can also be used to detect the transcription products of human RNA helicase 34 by performing RNA-polymerase chain reaction (RT-PCR) in vitro amplification.
- RNA helicase 34 gene can also be used to diagnose human RNA helicase 34-related diseases.
- Human RNA helicase 34 mutations include point mutations, translocations, deletions, recombinations, and any other abnormalities compared to the normal wild-type human RNA helicase 34 DNA sequence. Mutations can be detected using existing techniques such as Sou thern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, mutations may affect protein expression. Therefore, Nor thern blotting and Western blotting can be used to indirectly determine whether a gene is mutated.
- sequences of the invention are also valuable for chromosome identification. This sequence will specifically target a specific position on a human chromosome and can hybridize to it. Currently, specific sites for each gene on the chromosome need to be identified. Currently, only a few chromosome markers based on actual sequence data (repeating polymorphisms) are available for marking chromosome positions. According to the present invention, in order to associate these sequences with disease-related genes, an important first step is to locate these DNA sequences on a chromosome.
- PCR primers (preferably 15-35 bp) are prepared based on cDNA, and the sequence can be located to stain the hybrid cells that contain human genes corresponding to the primers to produce amplified fragments.
- PCR localization of somatic hybrid cells is a quick way to localize DNA to specific chromosomes.
- oligonucleotide primers of the present invention in a similar manner, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization.
- Other similar strategies that can be used for chromosomal localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and pre-selection of hybridization to construct chromosome-specific cDNA libraries.
- Fluorescent in situ hybridization (FI SH) of cDNA clones with metaphase chromosomes allows precise chromosomal localization in one step.
- FI SH Fluorescent in situ hybridization
- the difference in cDNA or genomic sequence between the affected and unaffected individuals needs to be determined. If a mutation is observed in some or all diseased individuals and the mutation is not observed in any normal individuals, the mutation may be the cause of the disease. Comparing affected and unaffected individuals usually involves first looking for structural changes in chromosomes, such as deletions or translocations that are visible at the chromosomal level or detectable with cDNA sequence-based PCR. According to the resolution capabilities of current physical mapping and gene mapping technology, the cDNA accurately mapped to the chromosomal region associated with the disease can be one of 50 to 500 potentially pathogenic genes (assuming 1 megabase mapping resolution) Capacity and each 20kb corresponds to a gene).
- the polypeptides, polynucleotides and mimetics, agonists, antagonists and inhibitors of the present invention can be used in combination with a suitable pharmaceutical carrier.
- suitable pharmaceutical carrier can be water, glucose, ethanol, salts, buffers, glycerol, and combinations thereof.
- the composition comprises a safe and effective amount of the polypeptide or antagonist, and carriers and excipients which do not affect the effect of the drug. These compositions can be used as drugs for the treatment of diseases.
- the invention also provides a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
- a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
- these containers there may be instructional instructions given by government agencies that manufacture, use, or sell pharmaceuticals or biological products, which prompts permission for administration on the human body by government agencies that produce, use, or sell.
- the polypeptides of the invention can be used in combination with other therapeutic compounds.
- the pharmaceutical composition can be administered in a convenient manner, such as by a topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal route of administration.
- Human RNA helicase 34 is administered in an amount effective to treat and / or prevent a specific indication.
- the amount and range of human RNA helicase 34 administered to a patient will depend on many factors, such as the mode of administration, the health conditions of the person to be treated, and the judgment of the diagnostician. Examples
- Total human fetal brain RNA was extracted by one-step method with guanidine isothiocyanate / phenol / chloroform.
- Quik mRNA I solat ion Ki t (Qiegene product) Isolate poly (A) mRNA from total RNA. 2ug poly (A) mRNA is reverse transcribed to form cDNA.
- the Smart cDNA cloning kit (purchased from Clontech) was used to insert the cDNA fragments into the multicloning site of pBSK (+) vector (Clontech) to transform DH5 cc, and the bacteria formed a cDNA library.
- Dye terminate cycle reaction sequencing kit Perkin-Elmer
- ABI 377 automatic sequencer Perkin-Elmer
- the determined cDNA sequence was compared with an existing public DM sequence database (GenebanJ), and it was found that the cDNA sequence of one of the clones OlclO was a new DNA.
- a series of primers were synthesized to determine the inserted cDNA fragments of the clone in both directions.
- CDNA was synthesized using fetal brain total RNA as a template and oligo-dT as a primer for reverse transcription reaction. After purification with Qiagene's kit, the following primers were used for PCR amplification:
- Primerl 5'- GGGAGGCTTTATCTGCAGTGCTGC-3 '(SEQ ID NO: 3)
- Primer2 5'- AAAGTAGTAAGGATTTTTATTGTC-3 '(SEQ ID NO: 4)
- Primerl is a forward sequence starting at lbp of the 5th end of SEQ ID NO: 1;
- Pritner2 is the 3, terminal reverse sequence of SEQ ID NO: 1.
- Amplification reaction conditions reaction volume containing 50 ⁇ 1 of 50mmol / L KC1, 10mmol / L Tris-HCl, pH8.5, 1.5mmol / L MgCl 2, 20 ( ⁇ mol / L dNTP, lOpmol primer, 1U Taq DNA polymerase (Clontech).
- the reaction was performed on a PE9600 DNA thermal cycler (Perkin-Elmer) under the following conditions for 25 cycles: 94 ° C 30sec; 55 ° C 30sec; 72 ° C 2min.
- RT -PCR was used to set P-actin as a positive control and template blank as a negative control.
- the amplified product was purified using a QIAGEN kit and linked to a pCR vector using a TA cloning kit (Irwitrogen).
- the results of DNA sequence analysis showed that The DNA sequence of the PCR product is identical to that of 1 to 2709bp shown in SEQ ID NO: 1.
- Example 3 Northern blot analysis of human RNA helicase 34 gene expression
- a 32P-labeled probe (about 2 x 10 6 cpm / ml) was hybridized with a nitrocellulose membrane to which RNA was transferred at 42 ° C overnight in a solution containing 50% formamide-25mM KH 2 P0 4 (pH7.4)-5 x SSC- 5 x Denhardt's solution and 20 ( ⁇ g / ml salmon sperm DNA. After hybridization, the filter was washed in 1 x SSC-0.1% SDS at 55 ° C for 30 minutes. Then, Analysis and quantification using Phosphor Imager.
- Example 4 In vitro expression, isolation and purification of recombinant human RNA helicase 34
- Primer3 5,-CCCCATATGATGGCTTCAAGACAACCAGAAGTG-3 '(Seq ID No: 5)
- Primer4 5'-CCCGAGCTCCTAGAAGCCAGTGGGTGTGAGCAC-3' (Seq ID No: 6)
- the 5 'ends of these two primers contain Ndel and Sacl restriction sites, respectively.
- the coding sequences of the 5 'and 3 ' ends of the gene of interest are followed, respectively.
- the Ndel and Sacl restriction sites correspond to the selectivity within the expression vector plasmid pET-28b (+) (Novagen, Cat. No. 69865.3). Digestion site.
- PCR reaction was performed using the pBS-0251cl0 plasmid containing the full-length target gene as a template.
- PCR reaction conditions were: 1 in a total volume of 50 ⁇ plasmid pBS- 0251cl0 containing 10pg, primer P ⁇ imer-3 P ⁇ imer-4 points and other] as 10pmol, Advantage polymerase Mix!
- Cycle parameters 94. C 20s, 60 ° C 30s, 68 ° C 2 min, a total of 25 cycles. Ndel and Sacl were used to double digest the amplified product and plasmid pET-28 (+), respectively, and large fragments were recovered and ligated with T4 ligase. The ligation product was transformed into colibacillus DH5c by the calcium chloride method.
- the positive clones were selected by colony PCR method and sequenced.
- a positive clone (pET-0251clO) with the correct sequence was selected, and the recombinant plasmid was transformed into E. coli BL21 (DE3) plySs (product of Novagen) using the calcium chloride method.
- the host bacteria BL21 (pET-0251clO) was cultured at 37 ° C to the logarithmic growth phase, and IPTG was added to a final concentration of 1 ol / L. , Continue to cultivate for 5 hours.
- the cells were collected by centrifugation, and the supernatant was collected by centrifugation. The supernatant was collected by centrifugation. An affinity column His. Bind Quick Cartridge was used which could bind 6 histidines (6His-Tag).
- NH2-Me tA la-Ser-Arg-G ln-Pro-G l u-Va l-Pro-Ala-Leu-G lu-A la-Ser-Ala-C00H (SEQ ID NO: 7).
- the polypeptide is coupled with hemocyanin and bovine serum albumin to form a complex, respectively.
- hemocyanin and bovine serum albumin For methods, see: Avrameas, et al. Immunochemi stry, 1969; 6: 43. Rabbits were immunized with 4 mg of the hemocyanin polypeptide complex plus complete Freund's adjuvant, and 15 days later, the hemocyanin polypeptide complex plus incomplete Freund's adjuvant was used to boost immunity once.
- a titer plate coated with a 15 g / inl bovine serum albumin peptide complex was used as an ELISA to determine antibody titers in rabbit serum.
- Total I gG was isolated from antibody-positive rabbit serum using protein A-Sepharose.
- the peptide was bound to a cyanogen bromide-activated Seph a r0 S e4B column, and the anti-peptide antibody was separated from the total I gG by affinity chromatography.
- the immunoprecipitation method proved that the purified antibody could specifically bind to human RNA helicase 34.
- Suitable oligonucleotide fragments selected from the polynucleotides of the present invention are used as hybridization probes in a variety of ways.
- the probes can be used to hybridize to genomic or cDNA libraries of normal tissue or pathological tissue from different sources to It is determined whether it contains the polynucleotide sequence of the present invention and a homologous polynucleotide sequence is detected.
- the probe can be used to detect the polynucleotide sequence of the present invention or its homologous polynucleotide sequence in normal tissue or pathology. Whether the expression in tissue cells is abnormal.
- the purpose of this embodiment is to select a suitable oligonucleotide fragment from the polynucleotide SEQ ID NO: 1 of the present invention as a hybridization probe, and to identify whether some tissues contain the polynucleoside of the present invention by using a filter hybridization method.
- Filter hybridization methods include dot blotting, Southern blotting, Nor thern blotting, and copying methods. They are all used to fix the polynucleotide sample to be tested on the filter and then hybridize using basically the same steps.
- the sample-immobilized filter is first pre-hybridized with a probe-free hybridization buffer, so that the non-specific binding site of the sample on the filter is saturated with the carrier and the synthetic polymer.
- the pre-hybridization solution is then replaced with a hybridization buffer containing the labeled probe and incubated to hybridize the probe to the target nucleic acid.
- the unhybridized probes are removed by a series of membrane washing steps.
- This embodiment utilizes higher-intensity washing conditions (such as lower salt concentration and higher temperature) to reduce the hybridization background and retain only strong specific signals.
- the probes used in this embodiment include two types: the first type of probes are oligonucleotide fragments that are completely the same as or complementary to the polynucleotide SEQ ID NO: 1 of the present invention; the second type of probes are partially related to the present invention
- the polynucleotide SEQ ID NO: 1 is the same or complementary oligonucleotide fragment.
- the dot blot method is used to fix the sample on the filter membrane. Under the high-intensity washing conditions, the first type of probe and the sample have the strongest hybridization specificity and are retained. First, the selection of the probe
- oligonucleotide fragments from the polynucleotide SEQ ID NO: 1 of the present invention for use as hybridization probes should follow the following principles and several aspects to be considered:
- the preferred range of probe size is 18-50 nucleotides
- Those that meet the above conditions can be used as primary selection probes, and then further computer sequence analysis, including the primary selection probe and its source sequence region (ie, SEQ ID NO: 1) and other known genomic sequences and their complements For homology comparison of the regions, if the homology with the non-target molecular region is greater than 85% or there are more than 15 consecutive bases, the primary probe should not be used generally;
- Probe 1 which belongs to the first type of probe, is completely homologous or complementary to the gene fragment of SEQ ID NO: 1 (41Nt):
- Probe 2 which belongs to the second type of probe, is equivalent to the replacement mutant sequence of the gene fragment of SEQ ID NO: 1 or its complementary fragment (41Nt):
- PBS phosphate buffered saline
- step 8-13 are only used when contamination must be removed, otherwise step 14 can be performed directly.
- NC membrane nitrocellulose membrane
- Two NC membranes are required for each probe in order to follow the experimental steps.
- the film was washed with high-strength conditions and strength conditions, respectively.
- the sample membrane was placed in a plastic bag, and 3-1 Omg pre-hybridization solution (lOxDenhardt's; 6xSSC, 0.1 mg / ral CT DNA (calf thymus DNA)) was added. After sealing the bag, shake at 68 ° C for 2 hours.
- 3-1 Omg pre-hybridization solution (lOxDenhardt's; 6xSSC, 0.1 mg / ral CT DNA (calf thymus DNA)
- Gene chip or gene microarray is a new technology currently being developed by many national laboratories and large pharmaceutical companies. It refers to the orderly and high-density arrangement of a large number of target gene fragments on glass. , Silicon and other carriers, and then use fluorescence detection and computer software to compare and analyze the data, in order to achieve the purpose of rapid, efficient, high-throughput analysis of biological information.
- the polynucleotide of the present invention can be used as target DNA for gene chip technology for high-throughput research of new gene functions; search for and screen new tissue-specific genes, especially new genes related to diseases such as tumors; diagnosis of diseases such as hereditary diseases .
- a total of 4,000 polynucleotide sequences of various full-length cDNAs are used as target DNA, including the polynucleotide of the present invention. They were amplified by PCR respectively. After purification, the concentration of the amplified product was adjusted to about 500 ng / ul, and spotted on a glass medium using a Cartesian 7500 spotter (purchased from Cartesian Company, USA). The distance between the points is 280ym. The spotted slides were hydrated and dried, cross-linked in a UV cross-linker, and dried after elution to fix the DNA on the glass slides to prepare chips. The specific method steps have been reported in the literature. The sample post-processing steps in this embodiment are:
- Total mRNA was extracted from human mixed tissues and specific tissues (or stimulated cell lines) in one step, and mRNA was purified with Oligotex mRNA Midi Kit (purchased from QiaGen).
- the fluorescent reagent Cy3dUTP 5-Amino-propargy 2'-deoxyuridine 5'-triphate coupled to Cy3 fluorescent dye (purchased from Amersham Phamacia Biotech) was used to label the mRNA of human mixed tissue, and the fluorescent reagent Cy5dUTP (5- Amino-propargy 1-2'-deoxyuridine) was used.
- Probes from the above two types of tissues were hybridized with the chip in a UniHyb TM Hybridization Solution (purchased from TeleChem) hybridization solution for 16 hours, washed with a washing solution (lx SSC, 0.2% SDS) at room temperature and scanned with ScanArray 3000.
- the instrument purchased from General Scanning Company, USA
- the scanned images were analyzed and processed with Imagene software (Biodiscovery Company, USA) to calculate the Cy3 / Cy5 ratio of each point.
- the above specific tissues are thymus, testis, muscle, spleen, lung, skin, thyroid, liver, PMA + Ecv30 4 cell line, PMA-Ecv304 cell line, and non-starved L02 cell line , Arsenic stimulated L02 cell line and prostate tissue for 1 hour. Plot a graph based on these 13 Cy3 / Cy5 ratios ( Figure 1). It can be seen from the figure that the expression profiles of human RNA helicase 34 and human RNA helicase 95 according to the present invention are very similar.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU46298/01A AU4629801A (en) | 2000-03-10 | 2001-02-26 | A novel polypeptide - human rna helicase 34 and a polynucleotide sequence encoding the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 00111965 CN1313395A (zh) | 2000-03-10 | 2000-03-10 | 一种新的多肽——人rna解旋酶34和编码这种多肽的多核苷酸 |
CN00111965.6 | 2000-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001070801A1 true WO2001070801A1 (fr) | 2001-09-27 |
Family
ID=4581861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2001/000244 WO2001070801A1 (fr) | 2000-03-10 | 2001-02-26 | Nouveau polypeptide, arn helicase humaine 34, et polynucleotide codant pour ce polypeptide |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1313395A (zh) |
AU (1) | AU4629801A (zh) |
WO (1) | WO2001070801A1 (zh) |
-
2000
- 2000-03-10 CN CN 00111965 patent/CN1313395A/zh active Pending
-
2001
- 2001-02-26 AU AU46298/01A patent/AU4629801A/en not_active Abandoned
- 2001-02-26 WO PCT/CN2001/000244 patent/WO2001070801A1/zh active Application Filing
Non-Patent Citations (3)
Title |
---|
J. BIOL. CHEM., vol. 268, no. 22, 1993, pages 16822 - 16830 * |
J. BIOL. CHEM., vol. 269, no. 47, 1994, pages 29838 - 29845 * |
J. BIOL. CHEM., vol. 270, no. 27, 1995, pages 16422 - 16427 * |
Also Published As
Publication number | Publication date |
---|---|
AU4629801A (en) | 2001-10-03 |
CN1313395A (zh) | 2001-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001068689A1 (fr) | Nouveau polypeptide, 1alpha sous-unite 13 humaine du facteur adaptatif de l'hypoxie, et polynucleotide codant pour ce polypeptide | |
WO2001075123A1 (fr) | Nouveau polypeptide, facteur nucleolaire hepatique 12, et polynucleotide codant pour ce polypeptide | |
WO2001070801A1 (fr) | Nouveau polypeptide, arn helicase humaine 34, et polynucleotide codant pour ce polypeptide | |
WO2001066575A1 (fr) | Nouveau polypeptide, actine 49, et polynucleotide codant pour ce polypeptide | |
WO2001066586A1 (fr) | Nouveau polypeptide, arn helicase humaine 13, et polynucleotide codant pour ce polypeptide | |
WO2001075039A2 (fr) | Nouveau polypeptide, arn helicase humaine 10, et polynucleotide codant pour ce polypeptide | |
WO2001092326A1 (fr) | Nouveau polypeptide, phosphatase acide 13, et polynucleotide codant ce polypeptide | |
WO2001072971A1 (fr) | Nouveau polypeptide, arn helicase humaine 10, et polynucleotide codant pour ce polypeptide | |
WO2001066592A1 (fr) | Nouveau polypeptide, arn helicase humaine 9, et polynucleotide codant pour ce polypeptide | |
WO2001094590A1 (fr) | Nouveau polypeptide, arn helicase humaine 10, et polynucleotide codant ce polypeptide | |
WO2001068873A1 (fr) | Nouveau polypeptide, molecule humaine d'adhesion intercellulaire 12, et polynucleotide codant pour ce polypeptide | |
WO2001074872A1 (fr) | Nouveau polypeptide, helicase d'arn humaine 15, et polynucleotide codant pour ce polypeptide | |
WO2001094371A1 (fr) | Nouveau polypeptide, proteine ribosomale humaine s4-10, et polynucleotide codant ce polypeptide | |
WO2001071003A1 (fr) | Nouveau polypeptide, serine protease humaine 8, et polynucleotide codant pour ce polypeptide | |
WO2001096534A1 (fr) | Nouveau polypeptide, arn helicase humaine 11 atp-dependante, et polynucleotide codant ce polypeptide | |
WO2001075117A1 (fr) | Nouveau polypeptide, tyrosinase humaine 12, et polynucleotide codant pour ce polypeptide | |
WO2001072801A1 (fr) | Nouveau polypeptide, proteine ribosomale humaine s11 12, et polynucleotide codant pour ce polypeptide | |
WO2001064721A1 (fr) | Nouveau polypeptide, adenosine triphosphatase 30, et polynucleotide codant pour ce polypeptide | |
WO2001072792A1 (fr) | Nouveau polypeptide, proteine humaine 13 analogue a l'ubiquitine, et polynucleotide codant pour ce polypeptide | |
WO2001066588A1 (fr) | Nouveau polypeptide, facteur humain 1-12 de liaison intensive de leucocytes, et polynucleotide codant pour ce polypeptide | |
WO2001070795A1 (fr) | Nouveau polypeptide, glycinamide ribonucleotide synthetase humaine 13, et polynucleotide codant pour ce polypeptide | |
WO2001079425A2 (en) | A novel polypeptide - human chloride channel protein 10 and the polynucleotide encoding said polypeptide | |
WO2001066576A1 (fr) | Nouveau polypeptide, glycoproteine amyloidogenique humaine 11, et polynucleotide codant pour ce polypeptide | |
WO2001073065A1 (fr) | Nouveau polypeptide, glycinamide ribonucleotide synthetase humaine 12, et polynucleotide codant pour ce polypeptide | |
WO2001075005A2 (fr) | Nouveau polypeptide, sous-unite c de l'atpase pompe a protons vacuolaire (v-atpase) 12, et polynucleotide codant pour ce polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |